NR3C1 and acute lymphoblastic leukemia: As discussed, steroid resistance in and of itself has been shown to confer poor prognosis and outcomes in ALL (18-20) and future directions of ALL therapy could perhaps concentrate on intensifying and enhancing GC efficacy and overcoming resistance by targeting specific players in the GC/GCR signaling pathways shown to be vital in this respect.